{"id":474,"date":"2014-11-21T10:24:22","date_gmt":"2014-11-21T01:24:22","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/?p=474"},"modified":"2024-03-18T10:32:31","modified_gmt":"2024-03-18T01:32:31","slug":"the-combination-of-hexokinase-2-and-pyruvate-kinase-m2-is-a-prognostic-marker-in-patients-with-pancreatic-cancer-mol-clin-oncol-3-563-571-2014","status":"publish","type":"post","link":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/archives\/474","title":{"rendered":"The combination of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer (Mol. Clin. Oncol., 3, 563-571, 2014.)"},"content":{"rendered":"<p><strong><span style=\"font-family: Georgia, 'Times New Roman', Times, serif;\"><a href=\"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2015.490\" target=\"_blank\" rel=\"noopener\">The combination of hexokinase 2\u00a0and pyruvate kinase M2 is a prognostic marker\u00a0in patients with pancreatic cancer (Mol. Clin. Oncol., 3, 563-571, 2014.)<\/a><\/span><\/strong><\/p>\n<p>Metabolism may determine the biologically\u00a0malignant behavior of pancreatic cancer. To investigate the\u00a0significance and prognostic value of cancer metabolism in\u00a0cancer patients, Ogawa et al.,\u00a0 in collaboration with the Department of Surgery, Osaka University, \u00a0investigated the expression of two key\u00a0enzymes in anaerobic glycolysis, hexokinase 2 (HK2) and\u00a0pyruvate kinase isoenzyme type M2\u00a0 (PKM2). The\u00a0results demonstrated that\u00a0the expression of HK2 and PKM2,\u00a0particularly their combination\u00a0may predict an unfavorable clinical\u00a0outcome in patients with pancreatic cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The combination of hexokinase 2\u00a0and pyruvate kinase M2 is a prognostic marker\u00a0in patients with pancreatic canc &hellip; <a href=\"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/archives\/474\" class=\"more-link\"><span class=\"screen-reader-text\">&#8220;The combination of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer (Mol. Clin. Oncol., 3, 563-571, 2014.)&#8221; \u306e<\/span>\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-474","post","type-post","status-publish","format-standard","hentry","category-results"],"aioseo_notices":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts\/474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/comments?post=474"}],"version-history":[{"count":3,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts\/474\/revisions"}],"predecessor-version":[{"id":1749,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts\/474\/revisions\/1749"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/media?parent=474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/categories?post=474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/tags?post=474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}